Clinical Trials Directory

Trials / Completed

CompletedNCT07284212

A Prospective Multicenter Cohort Study on Surgical Treatment Strategies for Pediatric Mitral Regurgitation

Status
Completed
Phase
Study type
Observational
Enrollment
427 (actual)
Sponsor
China National Center for Cardiovascular Diseases · Other Government
Sex
All
Age
14 Years
Healthy volunteers
Not accepted

Summary

This prospective, multicenter cohort study aims to evaluate the outcomes of surgical repair for pediatric mitral regurgitation (MR) in China. From March 2020 to December 2024, consecutive patients younger than 14 years who underwent mitral valve repair at eight representative congenital heart disease centers were enrolled. Eligible patients were those with at least moderate MR on preoperative echocardiography and no prior mitral valve surgery. Patients with uncorrectable concomitant cardiac anomalies, moderate or greater mitral stenosis, ischemic MR, severe leaflet dysplasia, connective tissue disorders (e.g., Barlow, Marfan), cardiomyopathies, or single-ventricle physiology were excluded. The primary endpoint is a composite of all-cause mortality, reoperation for cardiovascular causes, or recurrence of moderate-or-severe MR during follow-up. Secondary endpoints include perioperative outcomes such as postoperative hospital stay, intensive care unit stay, mechanical ventilation time, and hospitalization cost. This study is designed to provide high-quality prospective evidence on the safety, durability, and predictors of surgical repair for pediatric MR in a contemporary, real-world, multicenter setting. The findings may inform surgical decision-making and postoperative management strategies for this rare but challenging population.

Conditions

Interventions

TypeNameDescription
PROCEDUREconventional mitral valve repairPatients undergoing conventional mitral valve repair, including annuloplasty, leaflet cleft closure, chordal transfer, and chordal resection, et al.
PROCEDUREstandardized mitral valve repairPatients undergoing the standardized mitral valve repair strategy proposed by Professor Li at Fuwai Hospital in 2016, which involves comprehensive exploration and correction of abnormalities at the subvalvular, leaflet, and annular levels.

Timeline

Start date
2020-03-18
Primary completion
2025-09-20
Completion
2025-09-20
First posted
2025-12-16
Last updated
2025-12-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07284212. Inclusion in this directory is not an endorsement.